Allergan plc / SkinMedica, Inc.

Aesthetic Dermatology / Physician-Dispensed Topical Skincare

Disease Overview

Aesthetic dermatology covers physician-administered or physician-dispensed treatments for cosmetic concerns — facial wrinkles, volume loss, photoaging, pigmentation, and unwanted hair. The category sits at the intersection of cash-pay consumer skincare and prescription dermatology, with dermatologists, plastic surgeons, and medical spas as the dispensing channel.

Competitive Landscape

By late 2012 Allergan dominated the injectable side of facial aesthetics through Botox (onabotulinumtoxinA), Juvederm (hyaluronic acid filler family), and Latisse (bimatoprost for eyelash growth) — but had no presence in the adjacent physician-dispensed topical skincare segment, which was led by SkinMedica's TNS Recovery Complex/TNS Essential Serum (growth-factor-based), Allergan's competitor Galderma's Cetaphil RestoraDerm and Differin franchises, Valeant's Obagi Medical (tretinoin-based regimens), and Johnson & Johnson's Neutrogena Dermatologics. SkinMedica also brought Vaniqa (eflornithine), the only FDA-approved prescription product for unwanted facial hair in women. The $375M deal ($350M upfront + $25M sales earnout, Colorescience makeup line spun out) gave Allergan a ready-made physician-dispensed channel that complemented its injectables practice — same dermatologist and plastic-surgeon customer, deeper share of wallet, and a defensible position against Valeant/Obagi consolidation in the same segment [https://pmlive.com/pharma_news/allergan_to_pay_up_to_375m_for_skinmedicas_skincare_business_450712/]. Strategically the deal cemented Allergan as the only pure-play global aesthetics platform spanning injectables, devices, and topicals, and was a key reason Valeant later targeted Allergan in its 2014 hostile bid.